7th CML-CAB: Amsterdam, The Netherlands, 3-5 March 2019

On 3-5 March 2019, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its 7th meeting to discuss issues of major concern to the CML community. The meeting was made up of 3 sessions: Pfizer, Incyte/Takeda.

The following topics were discussed during the CML-CAB with Pfizer, Monday 4th March 2019, 14:00 – 18:00:

• Pfizer’s Updates: Organization & CML Strategy
• Access
• Bosulif Patient Experience
• TFR Patient Survey Update
• Discussion and Next Steps

7th CMLCAB March 2019 Pfizer Minutes Non-confidential

The following topics were discussed during the CML-CAB with Incyte/Takeda 5th March 2019, 08:00 – 15:00:

• Collaboration between the CML community and Takeda/Incyte & Partners
• Review of priority projects/engagements lead by Incyte with support of the CML community
• Ponatinib –Access, clinical application and research
• Takeda Commitment to CML, Discussion and Next Steps

7th CML CAB March 2019 Incyte and Takeda Minutes Non-confidential